Search

Your search keyword '"Andriani, Lilia"' showing total 7 results
Start Over Author "Andriani, Lilia"
7 results on '"Andriani, Lilia"'

1. Listeria monocytogenes Transmission from Donated Blood to Platelet Transfusion Recipient, Italy

Author

Gori, Maria, Bolzoni, Luca, Scaltriti, Erika, Andriani, Lilia, Marano, Vito, Morabito, Francesca, Fappani, Clara, Cereda, Danilo, Giompapa, Enza, Chianese, Rosa, Lanzini, Paola, Martinelli, Livia Antonietta, Bianchi, Silvia, Amendola, Antonella, Pongolini, Stefano, and Tanzi, Elisabetta

Subjects
Blood -- Medical examination, Blood platelets -- Transfusion, Listeria -- Health aspects, Biological products -- Health aspects, Tazobactam -- Health aspects, Resveratrol -- Health aspects, Blood donors -- Health aspects, Health
Abstract

Listeria monocytogenes is a gram-positive, primarily foodborne pathogen responsible for severe invasive infections (1), especially in immunocompromised patients. The treatment for some immunodeficiency conditions can require the administration of blood [...]

Published
2023
Full Text
View/download PDF

3. New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

Author

Carcione, Davide, primary, Intra, Jari, additional, Andriani, Lilia, additional, Campanile, Floriana, additional, Gona, Floriana, additional, Carletti, Silvia, additional, Mancini, Nicasio, additional, Brigante, Gioconda, additional, Cattaneo, Dario, additional, Baldelli, Sara, additional, Chisari, Mattia, additional, Piccirilli, Alessandra, additional, Di Bella, Stefano, additional, and Principe, Luigi, additional

Published
2023
Full Text
View/download PDF

4. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam

Author

Di Pilato, Vincenzo, primary, Principe, Luigi, additional, Andriani, Lilia, additional, Aiezza, Noemi, additional, Coppi, Marco, additional, Ricci, Silvia, additional, Giani, Tommaso, additional, Luzzaro, Francesco, additional, and Rossolini, Gian Maria, additional

Published
2022
Full Text
View/download PDF

5. A Two Amino Acid Duplication, L167E168, in the Ω-Loop Drastically Decreases Carbapenemase Activity of KPC-53, a Natural Class A β-Lactamase

Author

Piccirilli, Alessandra, primary, Cherubini, Sabrina, additional, Celenza, Giuseppe, additional, Rossolini, Gian Maria, additional, Brisdelli, Fabrizia, additional, Segatore, Bernardetta, additional, Principe, Luigi, additional, Luzzaro, Francesco, additional, Andriani, Lilia, additional, Amicosante, Gianfranco, additional, and Perilli, Mariagrazia, additional

Published
2022
Full Text
View/download PDF

6. Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians

Author

Principe, Luigi, primary, Lupia, Tommaso, additional, Andriani, Lilia, additional, Campanile, Floriana, additional, Carcione, Davide, additional, Corcione, Silvia, additional, De Rosa, Francesco, additional, Luzzati, Roberto, additional, Stroffolini, Giacomo, additional, Steyde, Marina, additional, Decorti, Giuliana, additional, and Di Bella, Stefano, additional

Published
2022
Full Text
View/download PDF

7. Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians

Author

Luigi Principe, Tommaso Lupia, Lilia Andriani, Floriana Campanile, Davide Carcione, Silvia Corcione, Francesco De Rosa, Roberto Luzzati, Giacomo Stroffolini, Marina Steyde, Giuliana Decorti, Stefano Di Bella, Principe, Luigi, Lupia, Tommaso, Andriani, Lilia, Campanile, Floriana, Carcione, Davide, Corcione, Silvia, Rosa, Francesco Giuseppe De, Luzzati, Roberto, Stroffolini, Giacomo, Steyde, Marina, Decorti, Giuliana, and Bella, Stefano Di

Subjects
β-lactams, β-lactamase inhibitors, cefiderocol, pharmacokinetics, pharmacodynamics, β-lactam, Drug Discovery, β-lactamase inhibitor, Pharmaceutical Science, Molecular Medicine, pharmacokinetic
Abstract

Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new β-lactam/β-lactamase inhibitors (BLs/BLIs) combinations has paid off and results from phase 3 and real-world studies are becoming available for several compounds. Cefiderocol warrants a separate discussion for its peculiar mechanism of action. Considering the complexity of summarizing and integrating the emerging literature data of clinical outcomes, microbiological mechanisms, and pharmacokinetic/pharmacodynamic properties of the new BL/BLI and cefiderocol, we aimed to provide an overview of data on the following compounds: aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam and meropenem/vaborbactam. Each compound is described in a dedicated section by experts in infectious diseases, microbiology, and pharmacology, with tables providing at-a-glance information.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results